DEF: Relmada Therapeutics Proposes Share Increase After 2025 Pivot

Relmada Therapeutics is seeking shareholder approval to increase authorized shares and equity incentives following a strategic turnaround and $100 million capital raise.

Summary

• Relmada successfully executed a corporate turnaround in 2025 after the failure of its former lead program, REL-1017, in late 2024.
• The company is seeking to increase authorized common shares from 150 million to 200 million to maintain financial flexibility.
• A proposal is on the table to increase the 2021 Equity Incentive Plan by 3.0 million shares to attract and retain talent.
• Cash reserves significantly improved to approximately $100 million as of late 2025, up from less than $10 million at its nadir.
• The company acquired two new clinical-stage assets: NDV-01 for bladder cancer and Sepranolone for Prader-Willi syndrome.
• Market capitalization recovered from a low of $7 million in March 2025 to a peak of $353 million in December 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a strong recovery story; however, the high level of executive compensation and the imminent dilution from the requested share increase temper the overall positive sentiment.

Positives

• Successfully raised $100 million in a November 2025 financing at market price with strategic investor participation.
• Extended operating runway significantly through disciplined expense management and capital allocation.
• Acquired NDV-01, which has early Phase II proof-of-concept data and a path to pivotal trials in 2026.
• Avoided NASDAQ delisting through proactive investor engagement and executive share purchases.
• Strengthened the clinical team with the addition of Dr. Raj Pruthi as Chief Medical Officer for Urology.

Negatives

• The previous lead program, REL-1017, failed to meet success criteria in late 2024, necessitating a total strategy shift.
• Significant dilution expected for existing shareholders if the increase in authorized shares and equity plan is approved.
• High executive compensation in 2025, with the CEO receiving over $8.8 million in total compensation, including large retention bonuses.
• The company remains pre-revenue and entirely dependent on capital markets for funding operations.

Risks

• Clinical development risk for new assets NDV-01 and Sepranolone, which are yet to enter pivotal Relmada-led trials.
• Regulatory risk regarding the upcoming FDA Investigational New Drug (IND) clearance for NDV-01 in mid-2026.
• Potential for further dilution as the company explicitly states the need for more authorized shares to raise future cash.
• Dependence on a small core management team to execute a multi-indication clinical program.

Future Outlook

Relmada enters 2026 focused on clinical execution for NDV-01 and Sepranolone. Key milestones include mid-2026 Phase 3 initiations for NDV-01 in bladder cancer and a Phase 2 initiation for Sepranolone in Prader-Willi Syndrome, with initial data readouts expected by year-end 2026.

Management Comments

• 2025 was a transformational year for Relmada—one that has meaningfully strengthened our foundation.
• Management and the Board acted decisively following the disappointing interim analysis of our former lead program.
• Relmada's most valuable asset was its experienced and capable clinical development organization.
• The challenging funding environment in the biotechnology sector created a unique opportunity to in-license promising programs.

Industry Context

StockSavvy.ai notes that Relmada's pivot from a failed CNS asset to oncology and rare disease assets is a classic 'biotech phoenix' strategy. By leveraging its existing NASDAQ listing and clinical infrastructure to acquire distressed but de-risked assets, the company has successfully bypassed the typical multi-year rebuild phase often seen after lead-asset failures.

Comparison to Industry Standards

• Executive compensation is benchmarked against the Radford Global Database for pre-commercial biotechnology companies.
• The $100 million capital raise at market price is superior to the typical 10-20% discounts seen in biotech secondary offerings.
• The proposed 33% increase in authorized shares is a standard defensive and strategic move for clinical-stage biotechs requiring multiple funding rounds.
• The pivot to NMIBC (bladder cancer) places Relmada in competition with established players like Merck (Keytruda) and specialized oncology firms.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings or regulatory matters disclosed.

Related Party Transactions

• Senior executives, including the CEO, made meaningful open-market share purchases in 2025 to restore market confidence.

Stakeholder Impact

• Shareholders face significant potential dilution from the 50 million share increase in authorized stock.
• Employees and management benefit from a refreshed equity incentive pool following the loss of value in previous options.
• Patients in the NMIBC and PWS communities may benefit from the accelerated development of acquired assets.

Next Steps

• Shareholder vote on May 27, 2026.
• File IND with the FDA for NDV-01 in mid-2026.
• Initiate Phase 3 trials for NDV-01 in bladder cancer.
• Initiate Phase 2 trial for Sepranolone in PWS.

Key Dates

Recommendation

While the turnaround is impressive and the cash position is strong, the company is entering a high-execution phase with new assets. Investors should wait for IND clearance and Phase 3 initiation before increasing positions, especially given the dilutive nature of the proposals in this proxy.

Keywords

Biotechnology, Oncology, Bladder Cancer, Prader-Willi Syndrome, Proxy Statement, Equity Incentive Plan, Clinical Trials, Capital Raise, Drug Development